Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line @entity2240 Treatment in XXXX .

@entity1 @entity1375 @entity137 @entity101 @entity2240 @entity294 @entity33 @entity17222 @entity1358 @entity8566 @entity1431
BACKGROUND: The aim was to assess the relationship between treatment efficacy and adverse events (AEs) for @entity1 with @entity1358 treated with first-line @entity2240 . @entity1 AND METHODS: 274 @entity1 were treated with @entity2240 (50 mg/d, 4-weeks-on and 2-weeks-off schedule). Physical and laboratory evaluations were done every sixth week. AEs were diagnosed at every visit. Clinical response was assessed every 3 months. The objective response rate (ORR), median progression-free (mPFS) and median overall survival ( @entity17222 ) and AEs were evaluated. Besides   (2) and log rank tests, multivariate Cox regression analysis and for synergism 1-sided t tests were used. RESULTS: The ORR was 25%. After a median follow-up of 32 months, the mPFS and @entity17222 were 9 and 19 months, respectively. @entity101 , @entity294 , @entity1375 , @entity33 , @entity8566 ( @entity8566 ), @entity137 , and @entity1431 were the most frequent treatment-associated AEs. Significantly longer (P  < .01) mPFS and @entity17222 were observed when @entity101 , @entity294 , @entity8566 , @entity1375 , @entity137 , or @entity1431 occurred. A statistically significant synergistic effect of the listed AEs was observed for progression-free survival (P  < .001) and overall survival (P  < .001). Multivariate analysis revealed that besides the prognostic category, the higher number of AEs (3-6 vs. 0-2) was an independent marker of longer mPFS (24 vs. 5 months, respectively; P  < .001) and @entity17222 (51 vs. 9 months, respectively; P  < .001). CONCLUSION: Results of this study provide evidence for the synergistically enhanced efficacy of @entity2240 treatment in @entity1 who present multiple AEs. These AEs are diagnosed routinely and their coexistence can help physicians to predict which group of @entity1 would benefit the most from first-line @entity2240 treatment.
